![](images/e5b51590e86e3a5a2b7ab925a2a727b965c52d05af9520d036ba2586f2b81b5e.jpg)  
FIGURE 1 - Combination of VEGFR and PDGFR tyrosine kinase inhibitors inhibits B16 melanoma tumor growth in vivo. (a) Subconfluent cultures of PAE/PDGFR  $\upbeta$  cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for  $1\ \mathrm{hr}$  on ice (left panels). Alternatively,PAE/PDGFR  $\mathbb{\beta}$  cells were incubated for  $5\;\mathrm{min}$  at  $37^{\circ}\mathbf{C}$  with conditioned medium or increasing amounts of PDGF-BB (right panels). PDGFR  $\cdot\upbeta$  phosphorylation was analyzed by  $\mathrm{PDGFR}{\upbeta}$   and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed fractions of cell lysates.  $\dot{(b)}$  B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle  $(\bullet)$   $3~{\upmu\mathrm{M}}$  STI571 (0), 1  $\upmu\mathrm{M}$  PTK787  $\mathbf{\Psi}(\mathbf{A})$  or  $3\ \upmu\mathrm{M}$  STI571 and  $1~\upmu\mathrm{M}$  PTK787  $(\bullet)$  B16/mock (c) or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57B16/J mice. When the tumor volume reached  $20~\mathrm{mm}^{3}$  , mice received either p.o. gavage of vehicle  $(\bullet)$  ，  $100~\mathrm{mg/kg/day}$  STI571 (),  $\dot{2}5\mathrm{~mg/kg/day}$  PTK787  $\mathbf{\Psi}(\mathbf{A})$  or  $100\;\mathrm{mg/kg/day}$  STI571 and  $25~\mathrm{mg/kg/day}$  PTK787  $(\bigcirc)$  Treatment was given for 13 days for mice bearing B16/mock tumors (c) and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by post hoc analysis applying the Duncan adjustment. Significance is shown for the last day of treatment: \*,  $p^{-}<0.05$  compared to vehicle treatment;  $\S$   $p<\dot{0}.05$  compared toPTK787 treatment; #,  $\bar{p}<0.05$  compared to STI571 treatment. (e) Sis-NIH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/STI571  $\mathcal{(25~\mathrm{mg/\bar{l}00}~\mathrm{mg/kg/da}}$  y; lanes 4 and 5), PTK787 (  $25~\mathrm{mg/kg/day}$  , lanes 6 and 7), ST1571 (  $\mathrm{{[00~mg/kg/day}}$  , lanes 8 and 9) or STI571  $(200~\mathrm{mg/kg/}$  day, lanes 10 and 11). PDGFR  $\cdot\upbeta$  was immunoprecipitated from  $15~\mathrm{mg}$  tumor lysate, and receptor phosphorylation was analyzed by PDGFR  $\upbeta$  and phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1). The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFR  $\mathring{\beta}$  band were compared to the first vehi cle-treated tumor to obtain the relative receptor phosphorylation.  

# Results  

# InvitrocharacterizationofaBl6F10melanomaclone whichproducesPDGF-BB  

A B16 melanoma cell line producing PDGF-BB (B16/PDGF-BB) was previously established.26 This cell line was used to isolate a clone with robust PDGF-BB production that was selected for further experiments. As shown in Figure 1a (left panels), conditioned medium from the selected B16/PDGF-BB clone, but not from a mock-transfected clone (B16/mock), induced strong PDGFRβ phosphorylation in porcine aortic endothelial cells transfected with the PDGFRβ (PAE/PDGFRB), indicating production of a large amount of PDGF-BB. The amount of PDGFBB released into the conditioned medium was estimated by incubatingPAE/PDGFR  $\cdot\upbeta$  cellswitheither conditionedmediumor increasing amounts of PDGF-BB. After 2 days, the B16/PDGFBB cells had released an amount of PDGF into the medium that was inexcess of  $0.5\ \mathrm{ng/ml}$  PDGF-BB (Fig. 1a, right panels). It should be noted that PDGF-BB sticks to both cells and plastic, so this amount is likely to represent underestimation of the productionofPDGF-BB.  